Scholarlink

Background <p>Childhood constipation is increasingly common, yet its prevalence is uncertain. This study examines comprehensive national data for trends in medically treated childhood constipation over a period of 18 years.</p> Methods <p>Included were all Swedish children, 0–14 years, 2006–2023, and all prescriptions for constipation, using the national Swedish Prescribed Drug register. The primary outcome was the number of unique patients prescribed, presented by age, gender, year, county, and ATC-code. Univariate and multivariable linear regression with ecological data were assessed for associations with age, gender, and year of prescription.</p> Results <p>The study population increased from 1.54 to 1.84&#xa0;million children 0–14 years, while constipation increased more than sixfold, from 1.2% in 2006 to 7.9% in 2023. Children 0–4 years were prescribed the most, with an increase from 1.6 to 9.5%. Female gender was associated with 7.5 higher prescription frequency per 1000 inhabitants when adjusted for age and year (4.6–10.5 95%CI, <i>p</i> &lt; 0.001). In 2023, girls aged 0–4 years were prescribed 27% more than boys (106.5 vs. 83.7 per 1000), compared with 23% among the 5–9-year-olds (86.8 vs. 70.6 per 1000), and 18% among the 10–14-year-olds (45.0 vs. 38.1 per 1000).</p> Conclusions <p>Prescription of constipation drugs to children has increased remarkably during the past 18 years. This study highlights an escalating public health challenge among children, with considerable associated costs for family and society.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epidemiology of childhood constipation: a national study of Swedish children from 2006 to 2023

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Helena Kornfält Isberg,
  • Kathy Falkenstein-Hagander,
  • Cecilia Lenander,
  • Mariette Derwig,
  • Lars Hagander

摘要

Background

Childhood constipation is increasingly common, yet its prevalence is uncertain. This study examines comprehensive national data for trends in medically treated childhood constipation over a period of 18 years.

Methods

Included were all Swedish children, 0–14 years, 2006–2023, and all prescriptions for constipation, using the national Swedish Prescribed Drug register. The primary outcome was the number of unique patients prescribed, presented by age, gender, year, county, and ATC-code. Univariate and multivariable linear regression with ecological data were assessed for associations with age, gender, and year of prescription.

Results

The study population increased from 1.54 to 1.84 million children 0–14 years, while constipation increased more than sixfold, from 1.2% in 2006 to 7.9% in 2023. Children 0–4 years were prescribed the most, with an increase from 1.6 to 9.5%. Female gender was associated with 7.5 higher prescription frequency per 1000 inhabitants when adjusted for age and year (4.6–10.5 95%CI, p < 0.001). In 2023, girls aged 0–4 years were prescribed 27% more than boys (106.5 vs. 83.7 per 1000), compared with 23% among the 5–9-year-olds (86.8 vs. 70.6 per 1000), and 18% among the 10–14-year-olds (45.0 vs. 38.1 per 1000).

Conclusions

Prescription of constipation drugs to children has increased remarkably during the past 18 years. This study highlights an escalating public health challenge among children, with considerable associated costs for family and society.